. Author manuscript; available in PMC: 2014 Feb 11.

Published in final edited form as: Breast Cancer Res Treat. 2013 May 17;139(2):607–616. doi: 10.1007/s10549-013-2562-6

Table 3.

Adjusted cognitive function scores by treatment over time (linear mixed-effects model)

Assessment	Overall		Standard chemotherapy^a		Capecitabine^b		p value^c
Assessment	CFS	SE	CFS	SE	CFS	SE	p value^c
Baseline	2.08	0.04	2.10	0.05	2.06	0.05	0.605
Mid-treatment	2.18	0.04	2.23	0.05	2.13	0.05	0.172
End of the treatment	2.21	0.04	2.29	0.05	2.13	0.05	0.024
12 months	2.19	0.04	2.21	0.05	2.17	0.05	0.573
18 months	2.19	0.04	2.23	0.05	2.19	0.05	0.546
24 months	2.21	0.04	2.26	0.05	2.13	0.05	0.065

Higher score = worse cognitive function. Covariates are age, treatment arm, assessment, and assessment–treatment arm interaction CFS cognitive function score, SE standard error

For standard treatment with doxorubicin and cyclophosphamide (AC), mid-treatment, day 29; end of the treatment, 4–5 months; for treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF): mid-treatment, day 77; end of the treatment, 6–7 months

For treatment with capecitabine: mid-treatment, day 63; end of the treatment, 4–5 months

p value compares standard and capecitabine treatment arms; a type 1 error rate was adjusted to 0.01 to reduce the chance of spurious significant findings